Evidence map›Paper›PMID 36698802›Full record

ArticleFrontiers in medicine2022

Patterns and factors associated with pneumococcal vaccination in a prospective cohort of 1,697 patients with rheumatoid arthritis.

Konstantinos Thomas, Argyro Lazarini, Evripidis Kaltsonoudis, Paraskevi V Voulgari, Alexandros A Drosos, Argyro Repa, Ainour Molla Ismail Sali, Prodromos Sidiropoulos, Panagiota Tsatsani, Sousana Gazi and 23 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 10 institutions in 1 country.

Konstantinos ThomasJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Argyro LazariniJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Evripidis KaltsonoudisRheumatology Clinic, University of Ioannina, Ioannina, Greece.
Paraskevi V VoulgariRheumatology Clinic, University of Ioannina, Ioannina, Greece.
Alexandros A DrososRheumatology Clinic, University of Ioannina, Ioannina, Greece.
Argyro RepaDepartment of Clinical Immunology and Allergy, University of Crete, Heraklion, Greece.
Ainour Molla Ismail SaliDepartment of Clinical Immunology and Allergy, University of Crete, Heraklion, Greece.
Prodromos SidiropoulosDepartment of Clinical Immunology and Allergy, University of Crete, Heraklion, Greece.
Panagiota TsatsaniRheumatology Unit, KAT Hospital, Athens, Greece.
Sousana GaziRheumatology Unit, KAT Hospital, Athens, Greece.
Kalliopi FragkiadakiJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Maria G TektonidouJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Petros P SfikakisJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Pelagia KatsimbriJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios BoumpasJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Evangelia ArgyriouRheumatology Unit, Sismanoglio Hospital, Athens, Greece.
Kyriaki A BokiRheumatology Unit, Sismanoglio Hospital, Athens, Greece.
Konstantina KaragianniDepartment of Rheumatology, University of Thessaly, Larissa, Greece.
Christina KatsiariDepartment of Rheumatology, University of Thessaly, Larissa, Greece.
Gerasimos EvangelatosRheumatology Unit, NIMTS Hospital, Athens, Greece.
Alexios IliopoulosRheumatology Unit, NIMTS Hospital, Athens, Greece.
Eleftheria P GrikaJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Panagiotis G VlachoyiannopoulosJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Theodoros Dimitroulas4th Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Alexandros Garyfallos4th Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Konstantinos MelissaropoulosRheumatology Unit, Agios Andreas Hospital, Patras, Greece.
Panagiotis GeorgiouRheumatology Unit, Agios Andreas Hospital, Patras, Greece.
Constantinos GeorganasPrivate Practitioner, Athens, Greece.
Periklis VounotrypidisPrivate Practitioner, Thessaloniki, Greece.
Konstantinos NtelisPrivate Practitioner, Kalamata, Greece.
Maria AretiPrivate Practitioner, Leivadia, Greece.
George D KitasJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios VassilopoulosJoint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRUniversity of Crete · GRUniversity of Ioannina · GRAgios Andreas Hospital · GRAristotle University of Thessaloniki · GRGeneral Hospital of Attica · GRNIMTS Hospital · GRSismanoglio General Hospital · GRUniversity of Thessaly · GRHellenic Agency for Local Development and Local Government · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with rheumatoid arthritis (RA) are at increased risk for serious infections. Pneumococcal vaccination is among the most important preventive measures, however, vaccine uptake is suboptimal. We explored the rate and factors associated with pneumococcal vaccination in a contemporary RA cohort. Materials and methods: Multi-center, prospective, RA cohort study in Greece. Patient and disease characteristics and influenza and pneumococcal vaccinations were documented at baseline and 3 years later. Results: One thousand six hundred and ninety-seven patients were included and 34.5% had already received at least one pneumococcal vaccine at baseline. Among 1,111 non-vaccinated patients, 40.1% received pneumococcal vaccination during follow-up, increasing the vaccine coverage to 60.8%. By multivariate analysis, positive predictors for pneumococcal vaccination included prescription of influenza vaccine (OR = 33.35, 95% CI: 18.58-59.85), history of cancer (OR = 2.35, 95% CI: 1.09-5.06), bDMARD use (OR = 1.85, 95% CI: 1.29-2.65), seropositivity (OR = 1.47, 95% CI: 1.05-2.05), and high disease activity (DAS28-ESR, OR = 1.33, 95% CI: 1.17-1.51). Male sex (OR = 0.65, 95% CI: 0.43-0.99) was a negative predictor for pneumococcal vaccination during follow-up. Discussion: Despite increasing rates of pneumococcal vaccine coverage, 40% of RA patients remain unvaccinated. Severe disease, bDMARD use, comorbidities, and more importantly flu vaccination were the most significant factors associated with pneumococcal vaccination, emphasizing the currently unmet need for cultivating a "vaccination culture" in RA patients.

Indexed as

biological therapycomorbiditiesinfectionsrheumatoid arthritisvaccination

Identifiers

PMID36698802
PMCPMC9868611
OpenAlexW4317243165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.